Evidence map

ArticleBlood2025

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.

Zhe Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

9 papers cite it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 40163809